#### **SEPSIS**

### **AMINOGLYCOSIDES**

**Examples:** streptomycin, gentamicin, tobramycin

#### Mechanism of action

A bactericidal group of drugs which inhibit bacterial protein synthesis by irreversibly binding bacterial ribosomes. They require entry to Gram negative bacterial cells through outer cell membrane (via porins) and inner cytoplasmic membrane (an oxygen-dependent system) in order to exert their effect. They have difficulty penetrating Gram positive cell walls.

They are therefore effective against Gram negative aerobic bacteria but not against anaerobic gram negative bacteria whose cell wall/membranes the antibiotic cannot penetrate. They have limited application against Gram positive bacteria.

Synergistic with penicillins - cell wall synthesis inhibitors increase the permeability of the cell wall to aminoglycosides.

They do not cross the blood brain barrier and have low concentrations in many tissues. They reach high concentrations in the inner ears and kidneys.

## **Adverse Effects**

**Ototoxicity** - accumulates in the endolymph and perilymph of the inner ear causing deafness, tinnitus and vertigo. Increased risk with co-use of loop diuretics and cisplatin.

**Nephrotoxicity** - retention of aminoglycosides by proximal tubular cells disrupts calcium-mediated transport processes resulting in nephrotoxicity. This ranges from mild, reversible renal impairment to severe, irreversible acute tubular necrosis. Dose, frequency and duration of therapy determine the extent of nephrotoxicity.

**Other adverse effects** - allergy, neuromuscular blockade. They cross the placenta and may cause congenital deafness.

# **Gentamicin Prescribing**

Where possible prescribe gentamicin using the Gentamicin calculator.

If critically ill and gentamicin is needed prescribe 5mg/kg actual body weight (max 400mg).

If critically ill and known CKD stage V give 2.5mg/kg (max 180mg).

Always prescribe gentamicin on the Gentamicin prescription chart.

Ertapenem <sup>†</sup>				em†	Ertapenem <sup>†</sup>		
		Meropenem <sup>†</sup> , Imipenem <sup>†</sup>	Meropene				
Ticarcillin-clavulanate, Piperacillin-tazobactam		3	ı-tazobactar	ate, Piperacillin	Ticarcillin-clavulanate, Piperacillin-tazobactam	Тіс	
Amoxycillin-clavulanate				nate	Amoxycillin-clavulanate	Amox	
				Cefepime			
	2		Ceftazidime				
				Ceftriaxone	Ce		
				ne	Cefuroxime		
Moxifloxacin				Moxifloxacin			
	im	Gentamicin/Tobramycin, Aztreonam	tamicin/Tobr	Ger			
	3 4		acin	Ciprofloxacin			
				Trimethoprim	n		
Nictionilidazoid						Daptomycin	
Metropidazole					າ, Linezolid,	Vancomycin/Teicoplanin, Linezolid,	Vancor
						Rifampicin/Fusidic Acid	Rifampicin/
Clindamycin						Clindamycin	
					Cephazolin		
					acillin	Flucloxacillin	
				Amoxycillin	Amo		
					Penicillin		
	7	rseudoffiolids	Proteus		ori eprococci	V O	NI NI
Anaerobes	ESC ADDIA*	Deput	bsiella	E.coli, Klebsiella	Ottoptooo:	Meev	MDOA
		Gram Negative Bacilli	Gram Nec		occi	<b>Gram Positive Cocci</b>	

Antibiotics in **bold** also cover Enterococcus Faecalis. For simplicity, atypical organisms are not shown.

\*ESCAPPM organisms are Enterobacter spp., Serratia spp., Citrobacter freundii, Aeromonas spp., Proteus spp., Providencia spp. & Morganella morganii. ESBL-producing organisms are **not** susceptible to most antibiotics containing a beta-lactam ring; carbapenems<sup>†</sup> are the usual agent of choice.